Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.
about
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protectionG-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and preventionSerelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy miceIncrease of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model.Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin)Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance.Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).Serelaxin and acute heart failure.Endothelial dysfunction and vascular disease - a 30th anniversary update.Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice.Dysfunction of endothelial progenitor cells in hyperlipidemic rats involves the increase of NADPH oxidase derived reactive oxygen species production.Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice.Effects of serelaxin on renal microcirculation in rats under control and high-angiotensin environments.Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure.Pulmonary arterial compliance and pulmonary hemodynamic effects of Serelaxin in a sheep model.Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model.Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.
P2860
Q26740185-38346249-9803-4E57-B3E7-8C9EF298D51DQ26744192-A48BC3D5-A5BB-4C19-8C10-32995C176F5FQ33623465-6716B03C-F5DA-4616-85E7-73762F0F0A9CQ35824916-87DE0578-DFA6-49BE-9FCB-550099A3ED97Q36073516-24BAD226-B197-4ED9-B060-CF6859C2B4C4Q36797528-A6C92A41-0F1F-4ECA-900F-3B6A145FD51CQ37571303-0D20B18C-2DAA-48F9-BF51-3FF55B11A69EQ37712528-72E6224A-3631-4C51-A343-940FDD8C710DQ37727924-14CBDAD8-D657-462B-8169-08AE0AF82C81Q38646840-0AA29BA2-33B8-464C-A50E-53B6829DA082Q38680112-0EC9FD2F-CCED-4973-B2E8-C7CBB8BAEB16Q40958055-E2028C68-ED73-4D69-A26A-267752C58CB8Q46421200-4A6776FC-E2CF-4F92-89A2-FE0D7C721C94Q46586252-321D2DF6-0573-49EA-B67F-1B7E0966C78CQ47619900-6EF3756B-E6AD-4BE4-915D-DF3B9D5DA840Q50091258-F4C01DFF-FFE5-41FF-B952-F502EF35FE51Q51014866-5C5E23A6-E29C-4D23-ACF7-2412CB558F71Q55078665-CA369AAF-2284-4E71-82D0-24B72E692DD7Q55209012-8FC7E88B-B275-4E28-B77A-9D1B72FB98C1
P2860
Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@ast
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@en
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@nl
type
label
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@ast
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@en
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@nl
prefLabel
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@ast
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@en
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@nl
P2860
P1476
Serelaxin reduces oxidative st ...... ensin II-induced hypertension.
@en
P2093
Chris Baylis
Mark W Cunningham
P2860
P304
P356
10.1152/AJPRENAL.00407.2014
P577
2014-10-08T00:00:00Z